Could a single pill replace a cocktail of Anti-Rejection drugs after liver transplant?

NCT ID NCT06280950

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study tests whether liver transplant patients can safely switch from a standard anti-rejection drug (tacrolimus) to a different drug (everolimus) to protect their kidneys. About 340 adults who received their first liver transplant will be followed for 18-20 months. The goal is to see if this change keeps the liver healthy while reducing kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: everolimus
What this could lead to: If successful, this could allow liver transplant patients to take fewer anti-rejection drugs, reducing kidney damage and simplifying their medication routine.
What could go wrong: This is an early phase 2 trial with 340 participants, so results may not apply to everyone. There is a risk of organ rejection or side effects from changing medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER TRANSPLANT

Contacts and locations

Locations

Baylor Medical Center (Site #: 71153)
RECRUITING

Dallas, Texas, 75246, United States
Duke University Medical Center (Site #: 71139)
RECRUITING

Durham, North Carolina, 27710, United States
Icahn School of Medicine at Mount Sinai (Site #: 71115)
RECRUITING

New York, New York, 10029, United States
Mayo Clinic Hospital Arizona (Site #: 71144)
RECRUITING

Phoenix, Arizona, 85054, United States
Northwestern University (Site #: 71110)
RECRUITING

Chicago, Illinois, 60611, United States
University of California, San Francisco (Site #: 71108)
RECRUITING

San Francisco, California, 94143, United States
University of Pennsylvania (Site #: 71111)
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Pittsburgh Medical Center (Site #: 71170)
RECRUITING

Pittsburgh, Pennsylvania, 15260, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.